Total

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024

Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m.

Key Points: 
  • Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m.
  • ET, to discuss fourth quarter and full year 2023 financial results and operational progress as well as to provide additional color on its strategic actions.
  • The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP operating expenses, and adjusted EBITDA.
  • Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.

Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

Retrieved on: 
Wednesday, February 28, 2024

PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Adjusted EBITDA for the fourth quarter of 2023 was $100.5 million, compared to $109.7 million in the fourth quarter of the prior year.
  • Cash flows from operations totaled $58.7M million in the fourth quarter and capital expenditures were $24.6M million.
  • ET on Wednesday, February 28, 2024, to discuss fourth quarter and full-year 2023 financial results, and forward-looking financial guidance.

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Retrieved on: 
Wednesday, February 28, 2024

Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.

Key Points: 
  • Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
  • The fourth quarter basic and diluted loss per share was $0.40, compared to $0.64 for the fourth quarter of 2022.
  • Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.
  • Immunocore will host a conference call today, February 28, 2024 at 8:00 A.M. ET/ 1:00 PM GMT, to discuss the fourth quarter and full year 2023 financial results and provide a business update.

Ready Capital Corporation Reports Fourth Quarter 2023 Results

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ready Capital Corporation (“Ready Capital” or the “Company”) (NYSE: RC), a multi-strategy real estate finance company that originates, acquires, finances, and services lower-to-middle-market (“LMM”) investor and owner occupied commercial real estate loans, today reported financial results for the quarter ended December 31, 2023.

Key Points: 
  • NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ready Capital Corporation (“Ready Capital” or the “Company”) (NYSE: RC), a multi-strategy real estate finance company that originates, acquires, finances, and services lower-to-middle-market (“LMM”) investor and owner occupied commercial real estate loans, today reported financial results for the quarter ended December 31, 2023.
  • “We continue to make progress on our business strategy of repositioning the capital acquired in our merger with Broadmark Realty Capital into our core lending strategies despite current challenges in the commercial real estate sector,” said Thomas Capasse, Ready Capital’s Chairman and Chief Executive Officer.
  • Certain MBS positions are considered to be non-distributable due to a variety of reasons which may include collateral type, duration, and size.
  • Servicing rights relating to the Company’s small business commercial business are accounted for under ASC 860, Transfer and Servicing.

Alignment Healthcare Reports Fourth Quarter and Full-Year 2023 Results; Provides Full-Year 2024 Financial Guidance

Retrieved on: 
Tuesday, February 27, 2024

“Alignment Healthcare is built to thrive in the current Medicare Advantage market with our clinical framework and data-driven operations,” said John Kao, founder and CEO.

Key Points: 
  • “Alignment Healthcare is built to thrive in the current Medicare Advantage market with our clinical framework and data-driven operations,” said John Kao, founder and CEO.
  • Adjusted gross profit also excludes an additional $1.5 million of equity-based compensation recorded within medical expenses
    All comparisons, unless otherwise noted, are to the twelve months ended Dec. 31, 2022.
  • Total revenue was $1,823.6 million, up 27.2% year over year
    Adjusted gross profit excludes depreciation and amortization of $21.7 million and selling, general, and administrative expenses of $307.4 million (which includes $59.3 million of equity-based compensation).
  • Adjusted gross profit also excludes an additional $7.5 million of equity-based compensation recorded within medical expenses
    As of Dec. 31, 2023, total cash was $202.9 million, and debt was $165.0 million (excluding unamortized debt issuance costs)
    Adjusted Gross Profit is reconciled as follows:

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.

Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

ROCKVILLE, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year of 2023 and associated Company developments.

Key Points: 
  • Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year 2022.
  • Fourth quarter 2023 net sales of GOCOVRI® increased 10% to $32.0 million compared to fourth quarter 2022; Full year 2023 net sales of GOCOVRI increased 15% to $119.6 million compared to full year 2022.
  • Full year 2023 operating loss (GAAP) was $(5.3) million; Full year 2023 operating earnings (non-GAAP)(2), were $125.1 million.
  • ROCKVILLE, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year of 2023 and associated Company developments.

Array Technologies, Inc. Reports Financial Results for the Fourth Quarter and Full Year 2023; Full year 2023 net income of $86 million; Record full year Adjusted EBITDA of $288 million

Retrieved on: 
Tuesday, February 27, 2024

ALBUQUERQUE, N.M., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Array Technologies (NASDAQ: ARRY) (“Array” or “the Company”), a leading provider of tracker solutions, software and services for utility-scale solar energy projects, today announced financial results for its fourth quarter and full year ended December 31, 2023.

Key Points: 
  • “We finished 2023 on a strong note with revenue of $1,577 million, which was ahead of our expectations.
  • Our global orderbook has increased to $1.8 billion fueled by $600 million in Q4 2023 bookings.
  • This will enable us to have our third consecutive year of delivering both adjusted EBITDA and adjusted EBITDA margin growth.
  • Array management will host a conference call to discuss their fourth quarter and full year 2023 financial results on February 27, 2024 at 5:00 p.m. Eastern Time.

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 27, 2024

Gross margin for the fourth quarter 2023 was 49% compared to 45% in the prior year period.

Key Points: 
  • Gross margin for the fourth quarter 2023 was 49% compared to 45% in the prior year period.
  • Operating expenses in the fourth quarter of 2023 were $50.8 million, compared with $35.7 million in the prior year period.
  • Net loss was $27.5 million for the fourth quarter of 2023, compared to a loss of $28.2 million in the prior year period.
  • Adjusted EBITDA was a loss of $23.3 million for the fourth quarter of 2023, compared to a loss of $21.7 million in the prior year period.

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Retrieved on: 
Tuesday, February 27, 2024

“Our unaudited, preliminary product sales for the fourth quarter of 2023 were first reported on January 8, 2024,” commented Michael F. Brigham, President and CEO of ImmuCell.

Key Points: 
  • “Our unaudited, preliminary product sales for the fourth quarter of 2023 were first reported on January 8, 2024,” commented Michael F. Brigham, President and CEO of ImmuCell.
  • “We have no changes to those figures.”
    Total sales during the three-month period ended December 31, 2023 were 30% above the comparable period ended December 31, 2022.
  • Fourth quarter 2023 production was limited by lower output during the month of October, which was caused by a previously disclosed contamination event in September 2023.
  • EBITDA of approximately ($2.6) million during the year ended December 31, 2023 is in contrast to EBITDA of $350,000 during the year ended December 31, 2022.